Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Colorectal Neoplasms 80Stomach Neoplasms 64Rectal Neoplasms 39Pancreatic Neoplasms 31Colonic Neoplasms 27Esophageal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 20Adenocarcinoma 19Neoplasms 18Cholangiocarcinoma 16Neoplasm Metastasis 15Adenocarcinoma Of Esophagus 14Biliary Tract Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Ovarian Neoplasms 10Gastrointestinal Neoplasms 7Gallbladder Neoplasms 7Carcinoma, Hepatocellular 7Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Locally Advanced Rectal Cancer 5Recurrence 4Lymphoma 4Carcinoma 4Bile Duct Neoplasms 4Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Peritoneal Neoplasms 3

Interventions

Paclitaxel 40Carboplatin 34Bevacizumab 29liposomal doxorubicin 20Specimen Handling 18Taxes 17olaparib 16Magnetic Resonance Spectroscopy 16pembrolizumab 15Gemcitabine 15Topotecan 13Immunoglobulin G 11Disulfides 11Biopsy 11mirvetuximab soravtansine 8niraparib 7Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Oxaliplatin × 1 year × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01081262 2026-05-29

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
50 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡